|Table of Contents|

The effects of arsenic trioxide on multiple myeloma and p38 MAPK pathway

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 01
Page:
169-172
Research Field:
Publishing date:

Info

Title:
The effects of arsenic trioxide on multiple myeloma and p38 MAPK pathway
Author(s):
ZHANG Shunji; GAO Yujuan; SU Yanhua
Department of Hematology，the First Affiliated Hospital of Harbin Medical University，Heilongjiang Harbin 150001，China.
Keywords:
multiple myeloma; arsenic trioxide; resistance; p38 MAPK pathway
PACS:
R733.3
DOI:
10.3969/j.issn.1672-4992.2021.01.038
Abstract:
Multiple myeloma (MM) is a clonal B-cell malignancy with an age-adjusted incidence，ranking the second most frequent hematological malignancy in many countries.Even though the advent of novel agents including bortezomib have nearly doubled the median survival time in the past decade，MM largely remains incurable with an eventual relapse of the disease and resistance to therapy.To date，arsenic trioxide (ATO) has been applied to treat MM and its multiple molecular mechanisms can effectively target complex pathogenesis and pathways of MM.However，low response rate and relatively common resistance to ATO remain challenging issues indicated by trials.Recently，p38 mitogen-activated protein kinase (MAPK) activation by ATO was suggested to contribute to the resistance of MM cells to ATO treatment and inhibition of p38 MAPK pathway could significantly enhance ATO-induced cytotoxicity in MM cells.Therefore，targeting p38 MAPK pathway could be the new way to increase the treatment efficacy of ATO and improve the treatment outcome in MM.

References:

［1］RLLIG C，KNOP S，BORNHUSER M.Multiple myeloma［J］.The Lancet，2015，385(9983)：2197-2208.
［2］MATTHES T，MANFROI B，HUARD B.Revisiting IL-6 antagonism in multiple myeloma［J］.Critical Reviews in Oncology/Hematology，2016，105：1-4.
［3］TERPOS E，INTERNATIONAL MS.Multiple myeloma：Clinical updates from the american society of hematology annual meeting，2017［J］.Clinical Lymphoma，Myeloma & Leukemia，2018，18(5)：321-334.
［4］KUMAR SK，DISPENZIERI A，LACY MQ，et al.Continued improvement in survival in multiple myeloma：changes in early mortality and outcomes in older patients［J］.Leukemia，2014，28(5)：1122-1228.
［5］GENADIEVA-STAVRIC S，CAVALLO F，PALUMBO A.New approaches to management of multiple myeloma［J］.Current Treatment Options in Oncology，2014，15(2)：157-170.
［6］ABRAMSON HN.The multiple myeloma drug pipeline-2018：A review of small molecules and their therapeutic targets［J］.Clinical Lymphoma，Myeloma & Leukemia，2018，18(9)：611-627.
［7］RAVANDI F.Arsenic trioxide：expanding roles for an ancient drug［J］.Leukemia，2004，18(9)：1457-1459.
［8］DOUER D，TALLMAN MS.Arsenic trioxide：new clinical experience with an old medication in hematologic malignancies［J］.J Clin Oncol，2005，23(10)：2396-2410.
［9］WEN J，CHENG HY，FENG Y，et al.p38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells［J］.British Journal of Haematology，2007，140(2)：169-180.
［10］SANCHEZ Y，AMRAN D，FERNANDEZ C，et al.Genistein selectively potentiates arsenic trioxide-induced apoptosis in human leukemia cells via reactive oxygen species generation and activation of reactive oxygen species-inducible protein kinases(p38-MAPK，AMPK)［J］.International Journal of Cancer，2008，123(5)：1205-1214.
［11］LIU Q，HILSENBECK S，GAZITT Y.Arsenic trioxide-induced apoptosis in myeloma cells：p53-dependent G1 or G2/M cell cycle arrest，activation of caspase-8 or caspase-9，and synergy with APO2/TRAIL［J］.Blood，2003，101(10)：4078-4087.
［12］WU X，SHI J，WU Y，et al.Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2［J］.Cancer Biology & Therapy，2014，10(11)：1201-1214.
［13］KAWANO Y，MOSCHETTA M，MANIER S，et al.Targeting the bone marrow microenvironment in multiple myeloma［J］.Immunological Reviews，2015，263：160-172.
［14］RIBATTI D，VACCA A.The role of inflammatory cells in angiogenesis in multiple myeloma［J］.Advances In Experimental Medicine and Biology，2014，816：361-376.
［15］HUSSEIN MA.Arsenic trioxide：A new immunomodulatory agent in the management of multiple myeloma［J］.Medical Oncology，2001，18：239-242.
［16］ABDI J，RASTGOO N，LI L，et al.Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis［J］.Journal of Hematology & Oncology，2017，10(1)：169.
［17］MANIER S，SALEM KZ，PARK J，et al.Genomic complexity of multiple myeloma and its clinical implications［J］.Nature Reviews Clinical Oncology，2017，14(2)：100-113.
［18］TEOH PJ，CHUNG TH，SEBASTIAN S，et al.p53 haploinsufficiency and functional abnormalities in multiple myeloma［J］.Leukemia，2014，28(10)：2066-2074.
［19］VAN DE DONK NW，SONNEVELD P.Diagnosis and risk stratification in multiple myeloma［J］.Hematology/Oncology Clinics of North America，2014，28(5)：791-813.
［20］MUNSHI NC，TRICOT G，DESIKAN R，et al.Clinical activity of arsenic trioxide for the treatment of multiple myeloma［J］.Leukemia，2002，16(9)：1835-1837.
［21］HUSSEIN MA，SALEH M，RAVANDI F，et al.Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma［J］.British Journal of Haematology，2004，125(4)：470-476.
［22］ELMAHI AY，NIU C，LI W，et al.Effects of arsenic trioxide alone and in combination with bortezomib in multiple myeloma RPMI 8266 cells［J］.Asian Pacific Journal of Cancer Prevention，2013，14(11)：6469-6473.
［23］JIAN Y，GAO W，GENG C，et al.Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels［J］.Oncology Letters，2017，14(3)：3243-3248.
［24］WANG X，ZHANG M.Synergistic effects of valproic acid and arsenic trioxide on RPMI8226 cells in vitro and the possible underlying mechanisms［J］.Molecular Medicine Reports，2015，12(1)：1449-1456.
［25］HE X，YANG K，CHEN P，et al.Arsenic trioxide-based therapy in relapsed/refractory multiple myeloma patients：A meta-analysis and systematic review［J］.Onco Targets and Therapy，2014，7：1593-1599.
［26］LI X，SUN WJ.The clinical activity of arsenic trioxide，ascorbic acid，ifosfamide and prednisone combination therapy in patients with relapsed and refractory multiple myeloma［J］.Onco Targets and Therapy，2015，8：775-781.
［27］BOMMERT K，BARGOU RC，STUHMER T.Signalling and survival pathways in multiple myeloma［J］.European Journal of Cancer，2006，42(11)：1574-1580.
［28］CHAUHAN D，LI G，HIDESHIMA T，et al.Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance［J］.Blood，2003，102(9)：3379-3386.
［29］GIAFIS N，KATSOULIDIS E，SASSANO A，et al.Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses［J］.Cancer Res，2006，66(13)：6763-6771.
［30］HIDESHIMA T.Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu［J］.Blood，2002，101(2)：703-705.
［31］MEDICHERLA S，REDDY M，YING J，et al.p38α-Selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma［J］.Anticancer Research，2008，28：3827-3834.
［32］WEN J，FENG Y，HUANG W，et al.Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition［J］.Leukemia Research，2010，34(1)：85-92.

Memo

Memo:
-
Last Update: 2020-11-30